DK1699459T3 - Fremgangsmåde til behandling af multipel sclerose - Google Patents

Fremgangsmåde til behandling af multipel sclerose

Info

Publication number
DK1699459T3
DK1699459T3 DK04806691T DK04806691T DK1699459T3 DK 1699459 T3 DK1699459 T3 DK 1699459T3 DK 04806691 T DK04806691 T DK 04806691T DK 04806691 T DK04806691 T DK 04806691T DK 1699459 T3 DK1699459 T3 DK 1699459T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
meca
treating multiple
a3rag
apnea
Prior art date
Application number
DK04806691T
Other languages
Danish (da)
English (en)
Inventor
Pnina Fishman
Yehuda Sara Bar
Lea Madi
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DK1699459T3 publication Critical patent/DK1699459T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Sewing Machines And Sewing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK04806691T 2003-12-29 2004-12-23 Fremgangsmåde til behandling af multipel sclerose DK1699459T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53271203P 2003-12-29 2003-12-29
PCT/IL2004/001160 WO2005063246A1 (en) 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1699459T3 true DK1699459T3 (da) 2007-10-08

Family

ID=34738826

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04806691T DK1699459T3 (da) 2003-12-29 2004-12-23 Fremgangsmåde til behandling af multipel sclerose

Country Status (10)

Country Link
US (1) US7465715B2 (de)
EP (1) EP1699459B1 (de)
JP (1) JP2007517019A (de)
CN (1) CN100423723C (de)
AT (1) ATE363907T1 (de)
DE (1) DE602004006895T2 (de)
DK (1) DK1699459T3 (de)
ES (1) ES2287804T3 (de)
PL (1) PL1699459T3 (de)
WO (1) WO2005063246A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1817079B1 (de) 2004-12-02 2008-07-30 Can-Fite Biopharma Ltd. Behandlung von entzündungen
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ATE502640T1 (de) 2006-01-26 2011-04-15 Us Gov Health & Human Serv Allosterische a3-adenosin-rezeptormodulatoren
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
JP5373599B2 (ja) * 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
EP2137202B1 (de) 2007-03-14 2017-06-21 Can-Fite Biopharma Ltd. Verfahren zur herstellung von ib-meca
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
US9199102B2 (en) * 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
EP3124970A1 (de) * 2011-04-22 2017-02-01 Kyoto University Verwendung des basischen myelinproteins als neuartiger genetischer faktor für rheumatoide arthritis
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
CN104159589A (zh) * 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201892008A1 (ru) * 2016-04-21 2019-06-28 Астросайт Фармасьютикалс, Инк. Соединения и способы лечения неврологических и сердечно-сосудистых состояний

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
WO1997033879A1 (en) * 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CZ294538B6 (cs) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující

Also Published As

Publication number Publication date
ATE363907T1 (de) 2007-06-15
PL1699459T3 (pl) 2007-12-31
WO2005063246A1 (en) 2005-07-14
US20060142237A1 (en) 2006-06-29
CN100423723C (zh) 2008-10-08
DE602004006895D1 (de) 2007-07-19
EP1699459B1 (de) 2007-06-06
JP2007517019A (ja) 2007-06-28
DE602004006895T2 (de) 2008-01-31
CN1901915A (zh) 2007-01-24
ES2287804T3 (es) 2007-12-16
US7465715B2 (en) 2008-12-16
EP1699459A1 (de) 2006-09-13

Similar Documents

Publication Publication Date Title
DK1699459T3 (da) Fremgangsmåde til behandling af multipel sclerose
MY146986A (en) Methods for treating interleukin-6 related diseases
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
SG116667A1 (en) Internal riser inspection system, apparatus and methods of using same.
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
CY1114925T1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
JO2755B1 (en) (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
BR0306583A (pt) Provisão e sincronização da lista de viagem preferida e do indicador de viagem
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2007117973A3 (en) Multiple-listing referral-tracking system
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
DK1841765T3 (da) Imidazo[4,5-C]pyridinforbindelse og fremgangsmåde til antiviral behandling
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2003093503A3 (en) Method for bioequivalence determination using expression profiling
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
WO2003094957A3 (en) Methods of therapy for inducing tolerance
TWI256388B (en) Pharmaceutical combination
JOP20220127A1 (ar) طرق علاج ارتفاع ضغط الدم الشرياني الرئوي
ATE444762T1 (de) Therapeutische zusammenseztungen zur toleranzinduktion